Navigation Links
Moffitt researchers say race affect likelihood of finding suitable stem cell donor
Date:9/10/2012

Researchers at Moffitt Cancer Center and colleagues have published a study describing the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT).

The study appeared in the August issue of Bone Marrow Transplantation.

The success of HCT depends on finding cell donors who are closely matched genetically; as the degree of mismatching increases, the success of unrelated donor HCT falls accordingly. A patient's ideal donor is a genetically matched sibling.

The search for a perfectly matched donor for all groups takes time and affects the progression to transplantation. The National Marrow Donor Program estimates that the genetically matched donor rate is 90 percent for Caucasian patients, 70 percent for Hispanics and Asians, and 60 percent for those of African ancestry.

"Using unrelated adult donors to facilitate HCT has provided major opportunities for patients without a matched sibling donor. In fact, the rate of unrelated donors now exceeds the rate of related donor HCT," said Joseph Pidala, M.D., M.S., assistant member of Moffitt's Blood & Marrow Transplant Department and a member of the Immunology Program. "Using data available at Moffitt, we sought to describe the determinants of a successful, unrelated donor search and to explore the contribution of donor identification versus patient characteristics leading to successful transplantation outcome."

According to Pidala, many patients can achieve prolonged, condition-free survival after unrelated donor HCT. There is, however, a need to understand "modifiable factors" that limit access to unrelated donor HCT.

The researchers concluded that the difficulties in finding well-matched donors in some minority groups were likely related to the degree of genetic heterogeneity within those groups, as well as their underrepresentation in donor pools.

They concluded that when compared to Caucasians, African-Americans, Hispanics and Native Americans have greater difficulty in finding a suitably matched unrelated donor, and less likelihood of successfully reaching HCT. Other barriers to HCT include age and disease progression.

"This research speaks to the need for reducing the time from HCT consultation to donor identification and HCT," Pidala said. "Survival benefit for HCT is dependent upon finding a suitable donor in a timely manner and addressing modifiable barriers to reaching HCT."

"Our data are consistent with the expectation that if suitable unrelated donors could be more expeditiously identified, patient outcomes would improve, particularly for racial and ethnic minorities and for patients with better performance status," concluded Pidala and his colleagues. "Increased representation of ethnic minorities within unrelated donor registries will increase the likelihood of finding a suitable donor."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers study childhood melanoma characteristics
2. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
3. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
4. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
5. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
6. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
7. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
8. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
9. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
10. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
11. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: